AbbVie Inc. (ABBV), 2025 Q1 earnings digest

$ABBV is releasing its Q1 2025 earnings results today. They reported an EPS of $2.46, surpassing expectations by $0.06, and revenue of $13.34B, which is 8.39% higher year-over-year. Key highlights include robust growth from their ex-Humira platform, particularly in immunology, and strong demand for Skyrizi and Rinvoq. However, Humira faced a significant sales decline, down nearly 50%. Future risks might include sector tariffs impacting guidance, but overall, the outlook remains positive. 📊💰 Check details in valueverge.com/ABBV.